论文部分内容阅读
复发或对柔红霉素和阿糖胞苷联合的一线治疗完全或部分耐药的急性髓性白血病患者52例,随机分为数量相等的二组。分别进入大剂量阿糖胞苷3g/m~2/天,加米托蒽醌(MTX)7mg/m~2/日(如>60岁,5mg)或胺苯吖啶(AMSA)120mg/m~2/日(如>60岁,90mg),共5天的方案。若有效进行6个疗程的维持治疗,包含阿糖胞苷100mg/m~2/12小时×5天和(或)MTX 7mg/m~2或AMSA120mg/m~2第1天。二组总有效率为50％,AMSA组和MTX组完全缓解(CR)率分别为46％和58％,无显著差异(P=0.415)。与CR率相关的仅有因素为首次CR期,首次CR短于和长于6个月者,CR率分别为36％和
Fifty-two patients with acute myeloid leukemia who had relapsed or had complete or partial resistance to daunorubicin and cytarabine combined with first-line treatment were randomly divided into two equal groups. Enter high-dose cytarabine 3g/m~2/day, methitosone (MTX) 7mg/m~2/day (eg >60 years, 5mg) or amikacin (AMSA) 120mg/m ~ 2 days (eg >60 years, 90mg) for a total of 5 days. If effective for 6 courses of maintenance therapy, include cytarabine 100mg/m~2/12 hours x 5 days and/or MTX 7mg/m~2 or AMSA 120mg/m~2 day 1. The total effective rate in the two groups was 50%. The complete remission (CR) rates in the AMSA group and the MTX group were 46% and 58%, respectively, and there was no significant difference (P=0.415). The only factor related to the CR rate was the first CR period, the first CR was shorter and longer than 6 months, and the CR rate was 36% and